Results 121 to 130 of about 2,738 (166)
Some of the next articles are maybe not open access.
Atherosclerosis Supplements, 2019
In Austria, about 12 patients per 1 million inhabitants are treated currently with lipoprotein (LP-) apheresis. In 2016 it has been suggested, that about 5000 patients were treated worldwide with LP-apheresis, more than half of them in Germany. Regular LP-apheresis aims to decrease apolipoprotein B-rich lipoproteins and to reduce cardiovascular events.
Kurt Derfler
exaly +3 more sources
In Austria, about 12 patients per 1 million inhabitants are treated currently with lipoprotein (LP-) apheresis. In 2016 it has been suggested, that about 5000 patients were treated worldwide with LP-apheresis, more than half of them in Germany. Regular LP-apheresis aims to decrease apolipoprotein B-rich lipoproteins and to reduce cardiovascular events.
Kurt Derfler
exaly +3 more sources
Lipoprotein apheresis: State of the art and novelties
Atherosclerosis Supplements, 2013Lipoprotein apheresis (LA) is an extracorporeal technique which permits the unselective or specific removal of lipoproteins, namely Low Density Lipoproteins (LDL), as well as other apolipoprotein B100-containing lipoproteins from plasma. LA represents a selective upgrade (with both clinical and metabolic advantages) from conventional forms of ...
STEFANUTTI, Claudia, Ulrich Julius
openaire +2 more sources
Current Opinion in Lipidology, 2010
Lipoprotein apheresis is being performed with increasing frequency, but better data collection and recording of clinical outcomes are needed. Setting up registries would facilitate this process.This review appraises recent articles that discuss the need for national registries and requirements for setting them up, the efficacy of lipoprotein apheresis ...
openaire +2 more sources
Lipoprotein apheresis is being performed with increasing frequency, but better data collection and recording of clinical outcomes are needed. Setting up registries would facilitate this process.This review appraises recent articles that discuss the need for national registries and requirements for setting them up, the efficacy of lipoprotein apheresis ...
openaire +2 more sources
Is Lipoprotein (a)—Apheresis Useful?
Therapeutic Apheresis and Dialysis, 2005Abstract: Numerous epidemiological investigations have shown the importance of cholesterol, and in particular low density lipoprotein (LDL), and of the lipoproteins in the development of coronary sclerosis. A continuing relationship between cholesterol levels and coronary morbidity has been established.
openaire +2 more sources
The scientific basis and future of lipoprotein apheresis
Therapeutic Apheresis and Dialysis, 2021AbstractLipoprotein apheresis plays a vital role in the management of the severe hyperlipidemias that predispose to atherosclerosis. Determinants of efficacy are the acute reduction in lipoproteins achieved by each apheresis procedure, their frequency, and the fractional catabolic rates and hence pool sizes of low‐density lipoprotein (LDL) or ...
openaire +3 more sources
Apheresis for severe hypercholesterolaemia and elevated lipoprotein(a)
Pathology, 2019Low-density lipoprotein (LDL)-cholesterol (LDL-c) and lipoprotein(a) [Lp(a)] are independent cardiovascular risk factors. Reduction of LDL-c leads to reduction in cardiovascular events, regardless of the method of reducing LDL-c levels. Lifestyle modification and drugs are first line treatment options.
Elisa, Waldmann, Klaus G, Parhofer
openaire +2 more sources
Current situation of lipoprotein apheresis in Saxony
Atherosclerosis Supplements, 2013This paper summarizes the situation pertinent to treatment via lipoprotein apheresis in the federal state of Saxony, Germany in 2010. In total, 119 predominately male patients were treated in 10 centers; the majority of the patients was older than the mean age of the general population.
U, Julius +4 more
openaire +2 more sources
Effects of lipoprotein apheresis on PCSK9 levels
Atherosclerosis Supplements, 2015PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) increases LDL cholesterol (LDL-C) levels by stimulating the degradation of Low Density Lipoprotein receptors (LDL-r). This protein is now of high interest because antibodies which inhibit its effect on LDL-r are being developed.
U, Julius +8 more
openaire +2 more sources
History of lipidology and lipoprotein apheresis
Atherosclerosis Supplements, 2017This review tells the story of atherosclerosis research in the beginning of the 20th century. It presents the significance of cardiovascular diseases and addresses major questions currently being discussed among lipidologists and the current thinking with respect to low LDL-cholesterol levels and HDL.
openaire +2 more sources
Pleiotropic effects of regular lipoprotein-apheresis
Atherosclerosis Supplements, 2017Lipoprotein(LP)-apheresis is the treatment of choice in patients suffering from severe familial hypercholesterolemia. A wide range of mechanisms has been claimed to be responsible for the known clinical benefit.Patients suffering from heterozygous familial hypercholesterolemia undergoing LP-apheresis either with direct adsorption of lipoproteins (DALI)
Helmut, Sinzinger +2 more
openaire +2 more sources